U.S. lawmakers ask Gilead about Sovaldi pricing

March 21 (Reuters) - U.S. lawmakers have asked for a briefing from Gilead Sciences Inc on the price of new hepatitis C drug Sovaldi.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.